Financial Times’ David Firn reports that an honest-to-goodness hES clinical trial is ready to start for the improvement of sensory motor abilities lost in stroke.
Labels: clinical trials, hESC, ReNeuron, stem cell therapy, stroke
Financial Times’ David Firn reports that an honest-to-goodness hES clinical trial is ready to start for the improvement of sensory motor abilities lost in stroke.
Labels: clinical trials, hESC, ReNeuron, stem cell therapy, stroke